ZBH stock: buy or sell?
August 23rd, 2019
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Should I buy ZBH stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Zimmer Biomet stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Zimmer Biomet stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 15 ratings published for ZBH stock in the last month. The general sentiment of these ratings is bullish for ZBH stock, with 11 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-29||Wells Fargo & Co||n/a||Outperform|
|2019-7-29||Robert W. Baird||Neutral||Outperform|
|2019-7-29||Jefferies Financial Group||n/a||Buy|
|2019-7-29||Credit Suisse Group||n/a||Underperform|
|2019-6-11||Sanford C. Bernstein||Underperform||Market Perform|
ZBH stock analysis
Zimmer Biomet ended today at $133.64 and fell a terrifying -2.53%.
Shares of Zimmer Biomet ended today at $133.64 and fell a terrifying -2.53%. Since price and SMA200d lines crossed up on July, ZBH climbed $15.83 (13.44%). Since May when SMA100d and SMA200d crossed up, ZBH price gained $19.92 per share (17.52%). On August 13th, ZBH hit new all time highs, pushing higher previous ATH of $139.77 recorded on August 12th. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Zimmer Biomet shares dropped -2.46% this week, ending at $133.64. Late July ZBH boosted an outstanding 8.22% in just one week.
In a weekly time frame, Zimmer Biomet stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, ZBH might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last price record Zimmer Biomet marked last week. By mid June ZBH price bounced up over the SMA of 40 weeks that acted as support stopping new slides. By mid May, SMA20w and SMA40w crossed up triggering a rise of 9.80%.
ZBH stock price history
ZBH stock went public on November 1st, 2017 with a price of $110.511. Since then, ZBH stock surged a 20.90%, with an average of 20.90% per year. If you had invested right after ZBH's IPO a $1,000 in ZBH stock in 2017, it would worth $209.00 today.
1: Adjusted price after possible price splits or reverse-splits.
ZBH stock historical price chart
ZBH stock reached all-time highs on August/13 with a price of $140.53.
ZBH stock price target is $143.40Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 13 price predictions for Zimmer Biomet stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-29||Wells Fargo & Co||Raises Target||$143.00||$150.00||4.9%|
|2019-7-29||Robert W. Baird||Upgrades||$132.00||$154.00||16.7%|
|2019-7-29||Raymond James||Raises Target||$145.00||$150.00||3.4%|
|2019-7-29||Morgan Stanley||Raises Target||$143.00||$150.00||4.9%|
|2019-7-29||Jefferies Financial Group||Raises Target||$150.00||$167.00||11.3%|
|2019-7-29||Credit Suisse Group||Reiterates||$101.00||$120.00||18.8%|
|2019-3-4||Morgan Stanley||Raises Target||$132.00||$143.00||8.3%|
|2019-2-5||SunTrust Banks||Raises Target||n/a||$135.00||-|
|2019-1-22||Stifel Nicolaus||Lowers Target||$150.00||$135.00||-10%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on April, Zimmer Biomet soared a fine 7.61%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Zimmer Biomet annual revenues inched a slightly fine 1.66% to $7,932.90 M USD from $7,803.30 marked in 2017. Nonetheless, its income margin (compared to revenues) plunged to -4.78%, that is $-379.20 million. Zimmer Biomet fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Zimmer Biomet TTM sales up to March 2019 were $7,890.80 and income $-307.80 M dollars. If we compare this TTM figures with the last reported annuality, we can review Zimmer Biomet business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, remained stable a neutral -0.53%. Similarly, profit margin (net income/sales) stayed stable at -4.78%.
|2013||$4,620 M||-||$761 M16.5%||-|
|2014||$4,673 M||1.15%||$720 M15.4%||-5.37%|
|2015||$5,998 M||28.34%||$147 M2.5%||-79.59%|
|2016||$7,684 M||28.11%||$306 M4.0%||108.10%|
|2017||$7,803 M||1.55%||$1,814 M23.2%||492.94%|
|2018||$7,933 M||1.66%||$-379.20 M-4.8%||-120.91%|
|TTM||$7,891 M||-0.53%||$-307.80 M-3.9%||-18.83%|
Quarterly financial resultsZimmer Biomet posted $1,975.50 M in sales for 2019-Q1, a -4.61% less compared to previous quarter. Reported quarter earnings marked $246.10 M with a profit margin of 12.46%. Profit margin skyrocketed a 55.97% compared to previous quarter when profit margin was -43.51%. When comparing revenues to same quarter last year, Zimmer Biomet sales marked an ugly correction and slightly fell a -2.09%.
|2017-Q2||$1,950 M||-||$184.20 M9.4%||-|
|2017-Q3||$1,820 M||-6.67%||$98.80 M5.4%||-46.36%|
|2017-Q4||$2,089 M||14.79%||$1,231.40 M58.9%||1,146.36%|
|2018-Q1||$2,018 M||-3.42%||$174.70 M8.7%||-85.81%|
|2018-Q2||$2,008 M||-0.50%||$185.00 M9.2%||5.90%|
|2018-Q3||$1,837 M||-8.51%||$162.20 M8.8%||-12.32%|
|2018-Q4||$2,071 M||12.76%||$-901.10 M-43.5%||-655.55%|
|2019-Q1||$1,976 M||-4.61%||$246.10 M12.5%||-127.31%|
Zimmer Biomet ownershipWhen you are planning to buy shares of a stock, it's worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Zimmer Biomet, 0.24% of all outstanding shares are owned by its staff.
Bearish positions for ZBH stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$27.4 B||$2.9 B||$3.9 B||$349.2 B||$3.4 B|
|Total shares||204.8 M||28.3 M||76.7 M||2,660.0 M||51.9 M|
|Float shares||204.3 M||27.6 M||75.5 M||2,630.0 M||51.6 M|
|- Institutional holdings (%)||91.8%||97.5%||92.4%||69.2%||112.1%|
|- Insider holdings (%)||0.2%||1.8%||3.6%||0.1%||0.7%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, August 23rd, 2019|
|Day range||$133.06 - $137.28|
|Average true range||$2.82|
|50d mov avg||$126.86|
|100d mov avg||$123.83|
|200d mov avg||$119.12|
Zimmer Biomet performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Zimmer Biomet, the comparison is made against CONMED, Globus Medical, , NuVasive, RTI Surgical, Smith & Nephew SNATS, Stryker and Wright Medical.
|SNNSmith & Nephew SN...||11.03%||24.53%||33.63%|
Zimmer Biomet competitorsWe selected a few stocks to conform a list of Zimmer Biomet competitors to review if you are interested in investing in ZBH:
- CONMED (CNMD)
- Globus Medical (GMED)
- NuVasive (NUVA)
- RTI Surgical (RTIX)
- Smith & Nephew SNATS (SNN)
- Stryker (SYK)
- Wright Medical (WMGI)
Latest ZBH stock news
- Seeking AlphaZimmer Biomet Holdings: Management Expects Modest GrowthMarch 22, 2019